BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
Name
1036985876-MIT.pdf
Description
Full printable version
Size
1.35 MB
Format
Adobe PDF
Checksum (MD5)
badd3c41675f9067d2af8a25fbf5cd55
Author(s)
Besada, Rana Hany
Advisor(s)
Michael T. Hemann.
Alternative Title
Immunotherapy in childhood B-cell acute lymphoblastic leukemia
Date Issued
2018
Publisher
Massachusetts Institute of Technology
Abstract
B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible for the most cancer-related deaths in children. Advances in chemotherapy over the past half-century have steadily increased the remission and survival of children with B-cell acute lymphoblastic leukemia to nearly 90%. However, the problems of minimal residual disease and relapsed and refractory disease persist. Personalized, targeted therapies have improved outcomes among the minority of patients for whom chemotherapy is ineffective. Immunotherapy, specifically bispecific T-cell engaging antibody therapy and chimeric antigen receptor T-cell therapy, has proven an effective treatment for relapsed and refractory B-cell acute lymphoblastic leukemia in children. These new modalities, however, have also introduced new adverse side effects to the treatment regimen. Though immunotherapy has increased remission and survival, more work must be done to reduce adverse effects and eliminate relapsed and refractory disease.
Description
Thesis: S.M., Massachusetts Institute of Technology, Department of Biology, 2018.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 18-21).
Subjects
Biology.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
Persistent DSpace Link
